Thermo Fisher Scientific Inc. $TMO Shares Acquired by Alesco Advisors LLC

Alesco Advisors LLC grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 18.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 657 shares of the medical research company’s stock after purchasing an additional 103 shares during the period. Alesco Advisors LLC’s holdings in Thermo Fisher Scientific were worth $266,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of TMO. GAMMA Investing LLC increased its holdings in shares of Thermo Fisher Scientific by 60,610.9% in the first quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company’s stock valued at $1,203,859,000 after purchasing an additional 2,415,346 shares during the period. Nuveen LLC acquired a new position in shares of Thermo Fisher Scientific in the first quarter valued at about $532,360,000. Sarasin & Partners LLP acquired a new stake in Thermo Fisher Scientific during the first quarter worth about $242,991,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth about $195,049,000. Finally, EdgePoint Investment Group Inc. acquired a new stake in Thermo Fisher Scientific during the first quarter worth about $172,139,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Marc N. Casper sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at approximately $56,937,881. The trade was a 0.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms recently commented on TMO. Robert W. Baird raised their target price on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a report on Thursday, July 24th. Scotiabank raised Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 target price on the stock in a report on Friday, July 11th. Raymond James Financial reaffirmed an “outperform” rating and set a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Barclays raised Thermo Fisher Scientific from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $490.00 to $550.00 in a report on Thursday, September 11th. Finally, Wall Street Zen lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Sunday, September 7th. Seventeen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $592.24.

Thermo Fisher Scientific Price Performance

TMO stock opened at $480.70 on Wednesday. The business has a fifty day moving average of $469.07 and a two-hundred day moving average of $450.41. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The stock has a market cap of $181.52 billion, a price-to-earnings ratio of 27.80, a price-to-earnings-growth ratio of 2.53 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $623.77.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter last year, the firm earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s payout ratio is presently 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.